Pediatric Praziquantel Consortium
Attention for PEDPZQ Consortium in German newspapers
On October 19, Merck KGaA, Darmstadt, Germany announced the donation to the World Health Organization (WHO) of the 500 millionth tablets to treat schistosomiasis in African countries. The extensive Press coverage* was clearly acknowledging the important role that the Pediatric Praziquantel Consortium is playing in the context of the actions towards the elimination of the disease.
Consortium presenting at the ASTMH 65th Annual Meeting
In September, the Pediatric Praziquantel Consortium got acceptance of the abstract ’Outcome of two phase I relative bioavailability studies in healthy volunteers after administration of the new pediatric ODT formulations of racemate Praziquantel (rac-PZQ) and of the active enantiomer of Praziquantel (L-PZQ)’ for ...
A story of schistosomiasis infection in Ghana
A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.
Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.
Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.
The pediatric formulation
A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that will use small, orally dispersible tablets with an acceptable taste.